Structure Therapeutics

Our full team came together for an inspiring company retreat giving us the opportunity to align our mission for the future. During three action-packed days with numerous breakout sessions and activities, we fostered stronger connections, reaffirmed our dedication to our core values and shared insights from our individual teams to help further advance our patient-focused vision of making medicines more accessible to all. See below for a highlight reel of some of the trip's best moments.

That's a wrap for #ADA2024! Our team enjoyed showcasing data from our Phase 1b/2a study of GSBR-1290, a #smallmolecule #GLP1 receptor agonist in development for people living with #obesity and #type2diabetes. Following our time at the event, we're feeling inspired by the work being done in our industry for patients and look forward to sharing more about our innovative science. 

In commemoration of the three-day Chinese #DragonBoatFestival celebration, the team at our Shanghai office hosted a series of activities true to Chinese tradition and culture. From knitting and making sachets to creating leaf fans, we enjoyed crafting while snacking on an assortment of dumplings and rice cakes. 

Our CEO Raymond Stevens recently spoke with CNBC Fast Money's Melissa Lee to discuss our progress with our #GLP1 receptor agonist drug, GSBR-1290, and its potential to become a best-in-class oral treatment for people living with #obesity, and the scalability of #smallmolecule drugs. Watch the full clip here:  https://lnkd.in/eiuBxUz7 

We're excited to launch a new employee spotlight series introducing you to some of the key players on our team! First up, meet our Director, Medical Writing Chelsea Olsen, PhD. As a valued leader and mentor, we're happy to have Chelsea within our clinical team to help run our clinical trials efficiently as we design #smallmolecule medicines to transform patients’ lives across the globe.

We're pleased to share positive topline data from our 12-week Phase 2a #obesity study of our oral, non-peptide GLP-1 receptor agonist, GSBR-1290, along with positive data from our capsule to tablet PK study. GSBR-1290 demonstrated clinically meaningful and statistically significant weight loss and generally favorable safety and tolerability result. We look forward to starting our Phase 2b study, which is on track to begin in the fourth quarter of this year. Read the full announcement here: https://lnkd.in/eJp_qPuS

With recent advances in structure-based #drugdiscovery approaches, oral #smallmolecule drugs now have the potential to surpass the manufacturing scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. Learn more about how we're harnessing structure-based drug design, coupled with our advanced computational technologies and world-class expertise, to potentially treat diseases like type 2 #diabetes, #obesity, and #cardiopulmonary diseases below. https://lnkd.in/dzthZsh3

Students, join us this summer! Our 10-12 week summer #internship program is designed for students interested in #lifesciences and #biotechnology. Interns have the opportunity to join our team in South San Francisco and gain practical experience within their chosen departments. For students interested in contributing to our vision of developing orally available hashtag #smallmolecule medicines to make a difference for those living with obesity, type 2 diabetes, and cardiopulmonary diseases, apply at the link below by May 22, 2024. https://lnkd.in/ePNjZnTe More details as follows: - In-person minimum 3 days a week (Tue/Thu and 1 flex day) in the office - Program begins in late June 2024 - This is a temporary role working up to 40 hours per week and the hourly rate is $25/hour

We're pleased to share financial results and recent corporate achievements for the first quarter of 2024 as well as upcoming plans to share topline GSBR-1290 Phase 2a 12-week obesity data. Read the full announcement here: https://lnkd.in/eZaDDkCu

Our CEO & Chairman Raymond Stevens enjoyed speaking with the team at Biotech2050 about his journey as a serial entrepreneur, the evolution of structure-based #drugdiscovery, and the strategies employed by our team at Structure to drive innovation and create impactful treatments for global health challenges.